NRC Stock Overview
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Neuronetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.53 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$0.94 |
| Beta | 2.44 |
| 1 Month Change | -10.42% |
| 3 Month Change | 15.95% |
| 1 Year Change | 95.18% |
| 3 Year Change | -62.22% |
| 5 Year Change | -76.44% |
| Change since IPO | -76.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRC | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -11.4% | -5.0% | -2.0% |
| 1Y | 95.2% | -13.6% | -0.3% |
Return vs Industry: NRC exceeded the German Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: NRC exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| NRC volatility | |
|---|---|
| NRC Average Weekly Movement | 13.3% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NRC's share price has been volatile over the past 3 months.
Volatility Over Time: NRC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 203 | Keith Sullivan | neurostar.com |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Neuronetics, Inc. Fundamentals Summary
| NRC fundamental statistics | |
|---|---|
| Market cap | €106.93m |
| Earnings (TTM) | -€28.34m |
| Revenue (TTM) | €66.98m |
1.6x
P/S Ratio-3.8x
P/E RatioIs NRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRC income statement (TTM) | |
|---|---|
| Revenue | US$71.35m |
| Cost of Revenue | US$17.74m |
| Gross Profit | US$53.61m |
| Other Expenses | US$83.79m |
| Earnings | -US$30.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 75.13% |
| Net Profit Margin | -42.31% |
| Debt/Equity Ratio | 173.4% |
How did NRC perform over the long term?
See historical performance and comparison